Cramer: Apple Is Th...
Health Care: Drugs
Allos Therapeutics Inc. (ALTH: NASDAQ)
$1.77 -0.01 | -0.56%
06/01/12 - 04:00 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 87.37M | 48.16M | 141.18M | 30.46M |
| Receivables | 15.26M | 12.08M | 4.86M | 2.00M |
| Inventories | 505.00K | 178.00K | 36.00K | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 115.83M | 113.17M | 167.14M | 87.86M |
| Property, Plant & Equipment, Gross | 5.50M | 5.52M | 4.75M | 4.21M |
| Accumulated Depreciation & Depletion | 4.03M | 3.28M | 2.58M | 2.90M |
| Property, Plant & Equipment, Net | 1.48M | 2.24M | 2.17M | 1.31M |
| Intangibles | 4.77M | 5.22M | 5.68M | 0.00 |
| Other Non-Current Assets | 0.00 | 116.00K | 391.00K | 175.90K |
| Total Non-Current Assets | 6.25M | 7.59M | 8.24M | 1.48M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 122.08M | 120.76M | 175.38M | 89.34M |
| Accounts Payable | 1.50M | 4.93M | 2.04M | 280.53K |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 20.96M | 22.56M | 15.84M | 9.88M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 21.81M | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 21.81M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 42.77M | 22.56M | 15.84M | 9.88M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 79.30M | 98.20M | 159.54M | 79.46M |
| Common Par | 106.00K | 105.00K | 104.00K | 81.24K |
| Additional Paid In Capital | 560.35M | 548.72M | 532.65M | 379.04M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -481.16M | -450.63M | -373.21M | -299.66M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 79.30M | 98.20M | 159.54M | 79.46M |
| Total Equity | 79.30M | 98.20M | 159.54M | 79.46M |
| Total Liabilities & Stock Equity | 122.08M | 120.76M | 175.38M | 89.34M |
| Total Common Shares Outstanding | 106.26M | 105.49M | 104.23M | 81.24M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 105.71M | 105.12M | 90.47M | 75.40M |
| Diluted Weighted Shares Outstanding | 105.71M | 105.12M | 90.47M | 75.40M |
| Number of Employees | 111 | 156 | 170 | 81 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with ALTH
- Portfolio NameUser Type
- UserSaveyn walter
- ContributorStocks Under-$10 Setting Up...
- Userrab 's
- Usergdean1
- User$5 stocks
- UserStocks Under $5
- UserLegal Tender II
- UserTop Picks Under $5 for 2011...
- ContributorTop Stock Picks Under $5 fo...
- UserWatch List - Healthcare / B...
Latest ALTH Headlines from TheStreet
- Monday's Top 10 Articles, Videos on TheStreet 04.09.12 | 03:04 pm
- Spectrum Pharma: The Growth Party is Over 04.09.12 | 06:04 am
- Allos Stock Gaps Down On Today's Open (ALTH) 01.20.12 | 09:01 am
- Biotech Stock Mailbag: Amarin, Spectrum, Arena 01.06.12 | 06:01 am
- Spectrum Pharmaceuticals CEO: "We Are Always Looking for the Diamond in the Rough."
12.01.11 | 06:12 am - Next Step for Amag's Board: Fire CEO, Sell the Company. 10.21.11 | 11:10 am
- Biotech Stock Mailbag: Keryx Pharma 10.14.11 | 06:10 am
- Activist Fund Manager Ups Stake in Amag Pharma to Stop Merger With Allos 10.10.11 | 10:10 am
- Spectrum Pharma Said to Make Bid for Allos 09.21.11 | 11:09 am
- Biotech Stock Mailbag: Vivus 09.16.11 | 05:09 am
Press Releases for ALTH
- Allos Therapeutics (Graphic: Business Wire) - Business Wire 05.24.12 | 07:05 pm
- Spectrum Pharmaceuticals And Allos Therapeutics Announce Extension Of Previously Announced Tender Offer For Shares Of Allos Therapeutics - Business Wire 05.10.12 | 07:05 am
- Spectrum Pharmaceuticals Commences Tender Offer For All Outstanding Shares Of Allos Therapeutics - Business Wire 04.16.12 | 08:04 am
- Allos Therapeutics, Inc. (ALTH) Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Spectrum Pharmaceuticals - PR Newswire 04.05.12 | 10:04 am
- Spectrum Pharmaceuticals To Acquire Allos Therapeutics: Acquisition Expected To Be Accretive On A Cash Basis In Q4 Of 2012 - Business Wire 04.05.12 | 07:04 am
- Allos Therapeutics Reports Fourth Quarter And Full Year 2011 Financial Results - Business Wire 03.06.12 | 04:03 pm
- Allos Therapeutics To Report Fourth Quarter And Full Year 2011 Results On March 6, 2012 - Business Wire 02.21.12 | 08:02 am
- Allos Therapeutics Requests Re-Examination Of CHMP Opinion On FOLOTYN® In PTCL At The European Medicines Agency - Business Wire 01.30.12 | 08:01 am
- Allos Therapeutics Announces Interim Results From Phase 1 Combination Study Of FOLOTYN® And Bexarotene Demonstrate Activity In Patients With Relapsed Or Refractory Cutaneous T-cell Lymphoma - Business Wire 01.30.12 | 08:01 am
- Allos Therapeutics Receives Negative Opinion From The CHMP On FOLOTYN - Business Wire 01.20.12 | 07:01 am
Partner Headlines for ALTH
- Company News for April 9, 2012 - Corporate Summary - Zacks 04.09.12 | 10:04 am
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Benzinga's M&A Chatter for Thursday April 5, 2012 - Benzinga 04.08.12 | 01:04 pm
- Futures Steer Lower; Spectrum Pharmaceuticals Dives - Investor's Business Daily 04.05.12 | 09:04 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 03.30.12 | 09:03 am
- Allos Narrows Loss - Analyst Blog - Zacks 03.07.12 | 09:03 am
- ALTH Seeks Review of Folotyn Verdict - Analyst Blog - Zacks 02.06.12 | 06:02 pm
- Loss Shrinks at AMAG, CEO Departs - Analyst Blog - Zacks 11.08.11 | 10:11 am
- Company News for November 4, 2011 - Corporate Summary - Zacks 11.04.11 | 10:11 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 10.25.11 | 09:10 am
